| abstract |
(57) [Summary] Formula (I) Wherein W is CH, R 1 is a residue of a 5- or 6-membered heteroaryl ring, or W is N, and R 1 is a 5- or 6-membered heteroaryl ring or A residue of an aryl ring wherein the heteroaryl or aryl ring is halo, cyano, hydroxy, C (1-6) alkyl (halo, hydroxy, amino, mono or perfluoro C (1-3) alkyl, carboxy or C (1-6) may be substituted by alkoxycarbonyl) C (3-7) cycloalkyl, C (1 -6) alkoxy, amino, mono- - or di -C (1-6) alkylamino, acylamino, carboxy, C (1-6) alkoxycarbonyl, carboxy C (1 -6) alkyloxy, C (1-6) alkylthio, C (1-6) alkylsulphinyl, C (1-6) Al 1 to 3 selected from killsulfonyl, sulfamoyl, mono- and di-C ( 1-6) alkylsulfamoyl, carbamoyl, mono- and di-C (1-6) alkylcarbamoyl, and heterocyclyl R 2 is an optionally substituted aryl or an optionally substituted heteroaryl ring; X is CH 2 or CHR 3 , wherein R 3 is C (1-6) alkyl, or R 3 is bonded to the ortho position of the aryl or heteroaryl ring of R 2 and may contain oxygen or nitrogen as a ring atom. May form a 7-membered ring); Y is C (1-3) alkylene or C (4-6) cycloalkylene], and a pyrimidone ring (when W is N) Includes sexual body The compounds, and salts thereof, preferably pharmaceutically acceptable salts, are inhibitors of the bacterial enzyme Staphylococcus aureus methionyl t-RNA synthetase (MRS) and are useful for treating bacterial infections . |